Immunopharmacology Comments

Tadekinig alfa has FDA orphan drug designation for the treatment of hemophagocytic lymphohistiocytosis (Dec 2017) and Still's disease, including adult-onset Still's disease (AoSD) and systemic juvenile idiopathic arthritis (sJIA) (Mar 2017). In Europe the EMA has granted orphan designation as a treament for haemophagocytic lymphohistiocytosis (as of Nov 2016). Tadekinig alfa binds to and inhibits pro-inflammatory activity of the elevated mature IL-18 that drives recurrent MAS-like flares.

Immunopharmacology Disease
Disease	X-Refs	Comment	References
Still's disease, adult onset	Disease Ontology: DOID:14256	Tadekinig alfa is an FDA orphan drug and Phase 2 clinical candidate for AoSD (see NCT02398435).	1